CXCL8 and asthma: While the monotherapy did not reach significant inhibition, the combination of LAS194046 0.1 nM and fluticasone propionate 1 nM reached significant inhibition of LPS-induced IL-8 and MPP9 release in peripheral blood neutrophils from severe asthma and COPD patients (Fig. 4A) as well as in neutrophils from sputum of COPD patients (Fig. 4B).